EBS

#3040
Emergent BioSolutions Inc. Common Stock
8.3 0 USD
-0.12%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
8.26
8.32
1年のレンジ
7.56
11.46
1日の変化
-0.12%
月次変化
-0.48%
6か月変化
-22.57%
1年の変化
-22.57%
以前の終値
8.3 1
Open
8.2 7
安値
8.2 6
High
8.3 2
ボリューム
583
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 428.25 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr. | Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry 医薬品メーカー（特殊・ジェネリック）
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-43.68
売上高対価格比率
0.69

Emergent BioSolutions Inc. Common Stock

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

ニュース